




Goldman Sachs 29th Annual Healthcare Conference

**Chris Viehbacher
President, North American Pharmaceuticals**

June 12, 2008


GSK – Geographically Diverse



Q1 2008 Sales
£5.7bn -3%

Consumer Healthcare – continuing strength

1Q08 sales £893 million +8%



Q1 performance in line with expectations

Issues

Avandia
(£230m*)

Generics
(£249m*)

Q1 performance in line with expectations

Issues

Avandia

Generics

Opportunities

Growth Drivers

New products

Consumer

O.E. Programme

Strong pharma performances in 1Q08

Advair	£954m	+10%
Vaccines	£436m	+10%
Lamictal	£290m	+16%
Valtrex	£249m	+9%
Requip	£94m	+15%
Avodart	£85m	+30%
Lovaza	£50m	+72%*
Boniva	£49m	+50%
Arixtra	£35m	+70%
Tykerb, Veramyst	£32m	>100%

Significant number of new product contributions

2007 Key launches

TykerbTM
lapatinib ditosylate

AriXtra[®]
(fondaparinux sodium)

-- New ACS indication --

Veramyst[™]
(fluticasone furoate)
Nasal Spray

ALTABAX[™]
retapamulin ointment, 1%

COREG CR[™]
Carvedilol Phosphate
extended-release capsules

Advair
in Japan

Cervarix[®]

Just approved...

ENTEREG[™]
(alvimopan)

For POI

ADVAIR DISKUS[™]

COPD exacerbations

AVODART[™]
(dutasteride)

(CombAT study)

Rotarix[™]
Rotavirus Vaccine,
Live, Oral

Treximet[™]

Prepandrix

Volibris[™]
ambrisentan

...2008 pending

Tyverb[®]
Lapatinib
(EU)

Kinrix[™]

BOOSTRIX[®]
Expanded age

PROMACTA[™]
(eltrombopag olamine)

REQUIP XL[™]
(ropinirole
extended-release tablets)

2008 Outlook for GSK

- *GSK: Strong fundamentals*
- *Challenging and fast changing environment*
- *Need to continue to adjust the business model*



GlaxoSmithKline